10 Jan PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

Posted at 17:28h in News

0 Likes

Share

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452 PDF Version PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa. and SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization...

Read More

10 Jan Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2)

Posted at 17:26h in News

0 Likes

Share

News Release Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) January 7, 2020 Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p<0.0001) with an improvement in adjusted means of 3.8...

Read More

07 Jan Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2)

Posted at 15:18h in News

0 Likes

Share

WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) —  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company...

Read More

03 Apr VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU)

Posted at 23:35h in News

0 Likes

Share

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor...

Read More

03 Apr VIZIMPRO® (DACOMITINIB) RECEIVES MARKETING AUTHORIZATION IN EUROPEAN UNION (EU) FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Posted at 19:46h in News

0 Likes

Share

Wednesday, April 03, 2019 - 05:42am EDT Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth...

Read More

28 Feb Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals®

Posted at 17:12h in News

0 Likes

Share

Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide commercial rights to APL-2 in all indications WALTHAM Mass., and CRESTWOOD, Ky., February...

Read More

28 Feb Apellis lands as much as $250M in financing from drug development company

Posted at 14:43h in News

0 Likes

Share

By Chris Larson  –  Reporter, Louisville Business First Feb 28, 2019 Apellis Pharmaceuticals Inc. has reached a deal with a globally oriented drug development company that could give Apellis as much as $250 million in financing through what Apellis calls "a novel, risk-sharing collaboration." Apellis, a Crestwood, Ky.-based...

Read More

01 Feb PFIZER RECEIVES POSITIVE CHMP OPINION FOR VIZIMPRO® (DACOMITINIB) FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR-ACTIVATING MUTATIONS

Posted at 19:49h in News

0 Likes

Share

Friday, February 01, 2019 - 04:17am EST   NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in the European...

Read More

03 Dec Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®

Posted at 20:00h in News

0 Likes

Share

CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory strategy in the United States for M923, Momenta’s proposed biosimilar to HUMIRA. Momenta had...

Read More

25 Oct Eisai Launches Anticancer Agent Lenvima®

Posted at 20:29h in News

0 Likes

Share

Eisai Launches Anticancer Agent Lenvima® (Lenvatinib Mesylate) In United Kingdom Indicated For Advanced Thyroid Cancer Refractory To Radioactive Iodine Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its U.K. subsidiary Eisai Europe Ltd. has launched its in-house developed novel anticancer agent Lenvima®...

Read More